GSK:LSEGSK plc Analysis

GSK plc trades around £1,915, markedly above its DCF‑derived fair value of roughly £654, implying a material overvaluation despite a modest upside estimate of only about 6%. Technicals are mixed: the 20‑day SMA sits just below price while the 50‑day SMA remains higher, the RSI hovers at 44 (neutral), and a bullish MACD histogram supports a short‑term bounce, yet volume is trending downwards and the broader trend is neutral. The company delivers a solid 3.55% dividend yield with a payout ratio under 50%, strong cash generation and a ROE exceeding 40%, suggesting dividend sustainability. Recent news adds nuance – a high‑profile Alzheimer’s trial was discontinued, but the UK regulator approved a new liver‑disease drug and GSK completed a $950 million acquisition to broaden its pipeline, while analysts collectively maintain a “hold” stance.